Meanwhile, the gene level of matrix metallopeptidase nine and tumor necrosis factor related to tumor metastasis exhibits a downward trend in SLC25A22-silenced cancer cells, indicating inhibition of GSH synthesis may play a critical role in the treatment of cancer metastasis (Wong et al., 2016)
Endotoxin contamination, heavy metals, and synthetic byproducts are real risks in lower-tier products
Heart palpitations are a common symptom of the condition
Trial dose range: 112mg, once weekly, subcutaneous Standard escalation: 2mg +2mg every 4 weeks 12mg (~20 weeks) Pharmacokinetics: half-life ~6 days
M.BubpJ.MoleL
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT